Clinical trials: Dementia, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Dementia
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Lewy Body Dementia (LBD), Alzheimer Dementia (AD)
Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias
This study is being done to research the usefulness of PET/CT imaging for measuring brain inflammation and its relation to Alzheimer's Disease Dementia and related dementias.
- Trial name
- NCT04786223
- Testing
- C-11 ER-176, Blood Test
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Val Lowe
Non-Hodgkin Lymphoma, B-cell
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell…
- Trial name
- JASPIS-01 (NCT06534437)
- Testing
- MEN1703, Glofitamab
- Where
- 35 sites in France, Poland and 2 more
- Volunteers
- 178 people
- Sponsor
- Ryvu Therapeutics SA
Huntington Disease
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
- Trial name
- NCT06826612
- Testing
- SPK-10001
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- Hoffmann-La Roche
Huntington's Disease
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
HDClarity will seek at least 2500 research participants at different stages of Huntington's disease (HD). The primary objective is to collect a high quality CSF sample for evaluation of biomarkers and pathways that will enable…
- Trial name
- HDClarity (NCT02855476)
- Where
- 40 sites in United States, Canada and 8 more
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University College, London
Alzheimer Disease
Implantable Vagus Nerve Stimulation Modulation of Coeruleus-Norepinephrine Network for Mild-Moderate AD Patients
A randomized controlled clinical study will be conducted in Xuanwu Hospital of Capital Medical University. This study initially explore the effect of selective vagus nerve(C fiber) stimulation on mild-to-moderate AD patients, in…
- Trial name
- NCT05575271
- Testing
- Vagus Nerve Stimulation Modulation of the Coeruleus-Norepinephrine Network
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Xuanwu Hospital, Beijing
AD - Alzheimer's Disease, MCI
A Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy
This is a non randomized, open-label Phase I study in Chinese participants. The goal of this clinical trial is to evaluate the safety and tolerability of a radioactive imaging agent called [18F]Flortaucipir Injection, which is…
- Trial name
- NCT07580703
- Testing
- [18F]Flortaucipir Injection
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Radiopharma
Alzheimer Disease, Amyloid
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein…
- Conditions
- Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
- Trial name
- NCT07787169
- Testing
- LY4405094, Florbetapir F18, Florbetaben F 18
- Where
- 19 sites in United States, China and 1 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Memory Complaint
Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study
A regional, single-center, prospective, observational academic cohort will follow subjects who previously participated in the INSIGHT study and who agree an extension of their follow-up in the INSIGHT-2 research for additional…
- Conditions
- Alzheimer Disease, Memory Complaint, Memory Disorders
- Trial name
- INSIGHT-2 (NCT05806697)
- Testing
- Electroencephalogram (EEG), Oculomotor tests, MRI
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Alzheimer Disease, Early Onset
Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau
The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a…
- Trial name
- FUS-AD (NCT06600880)
- Testing
- Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
PSP - Progressive Supranuclear Palsy
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.
- Trial name
- NCT07217665
- Testing
- AADvac1
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Adam Boxer
Parkinson Disease, REM Sleep Behavior Disorder
Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder
The study aims to systematically document the course of REM sleep behavior disorder (RBD) and investigate possible clinical and imaging biomarkers for disease progression and conversion risk to Parkinson's disease (PD), dementia…
- Conditions
- Parkinson Disease, REM Sleep Behavior Disorder, Dementia, Lewy Body
- Trial name
- NUK-RBD (NCT06629207)
- Testing
- PET/CT with 18-FDG, SPECT : 123 I-FP-CIT (DATSCAN), MRI
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Alzheimer Disease, Early Onset, Posterior Cortical Atrophy
MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY
Patients with Alzheimer's disease and with early onset of symptoms (<65 years) (AD-Y) have a multi-domain cognitive deficit, whereas memory disorders (typical of the elderly patient's AD) are less often in the foreground.
- Trial name
- PET-AL (NCT04150198)
- Testing
- TEP/IRM
- Where
- 2 sites in France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Alzheimer Disease
Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease
This single-arm, open-label clinical study systematically evaluates the efficacy and safety of Galcanezumab in patients with mild-to-moderate Alzheimer's disease (AD).
- Trial name
- NCT07323927
- Testing
- Galcanezumab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Xuanwu Hospital, Beijing
Pain, Dementia
Testing the Pain Clinical Practice Guideline
There are evidence based processes for assessment and management of pain using pharmacologic and nonpharmacological approaches. These were reviewed and included within the Pain Management Clinical Practice Guideline (Pain…
- Trial name
- NCT05858996
- Testing
- Pain-CPG-EIT, Pain-CPG-Education Only
- Where
- 11 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of Maryland, Baltimore
Dementia, Mild, Mild Cognitive Impairment
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial evaluating the efficacy and safety of mazdutide in 420 participants with type 2 diabetes (T2D) and…
- Conditions
- Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes
- Trial name
- NCT07083154
- Testing
- Mazdutide
- Where
- 8 sites in China
- Volunteers
- 420 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Alzheimer's Disease, Healthy Participants
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with…
- Trial name
- NCT07780383
- Testing
- BMS-986446
- Where
- 6 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease
Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl
The purpose of this research study is to determine the safety of a radiotracer 18F-Fluselenamyl using positron emission tomography (PET) imaging.
- Trial name
- NCT06439992
- Testing
- 18F-Fluselenamyl
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Huntington Disease
Innovative Imaging and Cognitive BIOmarkers to Predict Huntington's Disease Progression
Intro Huntington's disease (HD) patients suffer from motor, cognitive and behavioral impairments, with heterogeneous phenotypes and variable time course.
- Trial name
- I2BIO-HD (NCT05808153)
- Testing
- radiotracer injection
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Parkinson Disease, Parkinson Disease Dementia
Monoamine Oxidase B PET/CT in Various MAO-B-Related Disease
To evaluate the potential usefulness of 18F-FPyCO/SMBT-1 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various MAO-B-related disease patients.
- Conditions
- Parkinson Disease, Parkinson Disease Dementia, Parkinson's Disease and Parkinsonism
- Trial name
- NCT07685873
- Testing
- Diagnostic Test: 18F-FPyCO/SMBT-1
- Where
- 3 sites in China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University